Cirtuvivint plus PARP inhibitor in BRCA/HRD ovarian cancer

Who could benefit from this research

What this research studies

This project explores whether adding cirtuvivint to Olaparib can overcome PARP resistance in ovarian cancer patients with BRCA mutations or HRD. The research leverages preclinical data showing cirtuvivint may boost anti-tumor effects by altering RNA splicing, dampening Wnt signaling, and increasing R-loop formation. If successful, this combination could offer a new option for patients who currently face limited chances after PARP resistance. The team will use established ovarian cancer models to test the combination and study the underlying biology to guide potential clinical translation.

Why it matters

Where this research is happening

• University of Colorado Denver
  Aurora, United States Active

Researchers

• Principal investigator: Corr, Bradley — University of Colorado Denver
• Study coordinator: Corr, Bradley

Related research

Other NIH-funded projects on the same topics.

• Mitotic MTH1 Inhibitors for Platinum-Resistant Ovarian Cancer

  A treatment approach targeting a specific cancer cell weakness (MTH1) to help women whose ovarian cancer stopped responding to platinum-based therapy.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11421329

• Targeting cancer-specific protein variants to guide T-cell therapy in platinum-resistant ovarian cancer

  Aims to find unique protein variants in platinum-resistant ovarian cancer to guide T-cell receptor therapy for patients.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11332288

• Why some ovarian cancers resist platinum chemotherapy: changes in tumor metabolism

  This project looks at how ovarian tumors change their metabolism when they stop responding to platinum chemotherapy and seeks new targets and markers to help women with recurrent high-grade serous ovarian cancer.

  NIH research Jesse Brown VA Medical Center · Chicago, United States · NIH-11212826

• Cirtuvivint plus olaparib for BRCA/HRD ovarian cancer that stopped responding to platinum

  This work adds cirtuvivint to the PARP drug olaparib to try to help people with BRCA-mutated or homologous recombination–deficient ovarian cancer that no longer responds to platinum chemotherapy.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11179129

• Finding new treatments for platinum-resistant ovarian cancer using T-cell therapy

  This study is looking for new ways to help patients with tough-to-treat ovarian cancer by analyzing their tumor samples to find specific targets that can be attacked by the immune system, which could lead to better treatments for them.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11115806

• Exploring how ovarian cancer cells change metabolism to resist treatment

  This study is looking into why some patients with high-grade serous ovarian cancer stop responding to standard platinum treatments, and it hopes to find new ways to help those patients by understanding how their cancer cells change and adapt.

  NIH research Jesse Brown VA Medical Center · Chicago, United States · NIH-10950330

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.